Selegiline transdermal system in major depressive disorder

Abstract

Few methods are available to explore the impact of neurocognition in schizophrenia on behaviors performed in usual contexts. The authors developed a video ethnography approach to examine the relationship between naturalistic behaviors and research constructs of neurocognition. Video ethnographers accompanied subjects through usual routines gathering continuous video data. Researchers developed codes to measure four behavioral domains observed on video. This paper describes the psychometric characteristics to be considered in the development of observational approaches. It also highlights differences between behaviors performed in usual environments and neuropsychological constructs. The authors demonstrate that everyday behaviors that have been shown to correspond to neurocognitive skills in a pilot feasibility study can be identified and rated. They further suggest that observational methods could provide novel strategies for linking research findings and clinical concerns.

Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials

“…15 In fact, a number of newer formulations of antidepressants with improved safety and tolerability profiles with different drug delivery technologies have been introduced in the current market. [16][17][18][19] The U.S. Food and Drug Administration (FDA) approved the selegiline transdermal system (STS) for the treatment of MDD in February 2006, and it has now become the first skin (transdermal) patch indicated for MDD. 16,17 In clinical trials with STS, it has been shown to be efficacious and safe in patients with MDD; there were no reports of hypertensive crisis associated with STS, and 6 of the 7 clinical trials were conducted without dietary modifications at any dose.…”

“…16,17 In clinical trials with STS, it has been shown to be efficacious and safe in patients with MDD; there were no reports of hypertensive crisis associated with STS, and 6 of the 7 clinical trials were conducted without dietary modifications at any dose. 18 A metaanalysis of all 5 short-term trials evaluating treatment effects of STS for patients with MDD has been previously reported. 20 According to the results, STS demonstrated significant treatment effects on core depression symptoms (HAM-D Bech 6 items: depressed mood, guilt, work and activities, retardation, psychic anxiety, general somatic symptoms), reverse vegetative symptoms (oversleeping, overeating), motor retardation, suicide, and genital symptoms (libido).…”

“…The U.S. Food and Drug Administration (FDA) approved the selegiline transdermal system (STS) for the treatment of MDD in February 2006, and it has now become the first skin (transdermal) patch indicated for MDD 16 , 17 . In clinical trials with STS, it has been shown to be efficacious and safe in patients with MDD; there were no reports of hypertensive crisis associated with STS, and 6 of the 7 clinical trials were conducted without dietary modifications at any dose 18 . A meta-analysis of all 5 short-term trials evaluating treatment effects of STS for patients with MDD has been previously reported 20 .…”